DrugBiological
Tabalumab clinical trials
Also written LY2127399.
- studies test it
- 20
- open now
- 0
- in phase 3
- 9
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
20 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 4 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 0
Eli Lilly and Company (19) · Applied Molecular Evolution (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tabalumab is read from its arms, and is right about nine times in ten.
Testing it · 20
- A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)CompletedPhase 2Eli Lilly and CompanyNCT01602224Written as Tabalumab
- A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid ArthritisCompletedPhase 2Eli Lilly and CompanyNCT00308282Written as LY2127399
- A Study of Japanese Rheumatoid Arthritis ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01253291Written as LY2127399
- A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor TherapyCompletedPhase 2Eli Lilly and CompanyNCT00689728Written as LY2127399
- A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedPhase 2Eli Lilly and CompanyNCT00882999Written as LY2127399
- A Study for Japanese Participants With Rheumatoid Arthritis (RA)CompletedPhase 1Eli Lilly and CompanyNCT01253226Written as LY2127399 (Tabalumab)
- A Study of LY2127399 in Participants With Systemic Lupus ErythematosusCompletedPhase 3Eli Lilly and CompanyNCT01205438Written as LY2127399
- A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyCompletedPhase 2Eli Lilly and CompanyNCT00785928Written as LY2127399
- A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With LupusTerminatedPhase 3Eli Lilly and CompanyNCT02041091Written as Tabalumab Auto-Injector
- A Study of LY2127399 in Participants With Systemic Lupus ErythematosusCompletedPhase 3Eli Lilly and CompanyNCT01196091Written as LY2127399
- An Open Label Study for Participants With Rheumatoid ArthritisTerminatedPhase 3Eli Lilly and CompanyNCT01215942Written as LY2127399
- On Open-Label Study in Participants With Systemic Lupus ErythematosusTerminatedPhase 3Eli Lilly and CompanyNCT01488708Written as LY2127399
- A Study in Participants With End-Stage Renal DiseaseCompletedPhase 2Eli Lilly and CompanyNCT01200290Written as LY2127399
- A Study in Participants With Rheumatoid ArthritisTerminatedPhase 3Eli Lilly and CompanyNCT01202773Written as LY2127399
- A Rheumatoid Arthritis Study in Participants on a Background Treatment of MethotrexateTerminatedPhase 3Eli Lilly and CompanyNCT01198002Written as LY2127399
- Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)TerminatedPhase 3Eli Lilly and CompanyNCT01676701Written as Tabalumab Auto-Injector
- A Study of LY2127399 in Rheumatoid ArthritisTerminatedPhase 2Eli Lilly and CompanyNCT01576549Written as LY2127399
- A Rheumatoid Arthritis Study in ParticipantsCompletedPhase 3Eli Lilly and CompanyNCT01202760Written as LY2127399
- An Open Label Extension Study in Participants With Rheumatoid ArthritisCompletedPhase 2Eli Lilly and CompanyNCT00837811Written as LY2127399
- A Phase 1 Safety Study of LY2127399 in Combination With BortezomibCompletedPhase 1Applied Molecular EvolutionNCT00689507Written as LY2127399
Given in every arm · 1 — tabalumab is usual care beside what is tested
Codes
What other systems call tabalumab · ClinicalTrials.gg INT006164
- MeSH (NLM) C575974tabalumabConfirmed NLM, Wikidata
- UNII (FDA) PQP8VH3MJWTABALUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7672878tabalumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91727TabalumabOne source FDA
- DrugBank DB11657One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575974 | tabalumab | Confirmed NLM, Wikidata |
| UNII (FDA) | PQP8VH3MJW | TABALUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7672878 | tabalumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91727 | Tabalumab | One source FDA |
| DrugBank | DB11657 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.